GTC Biotherapeutics (GTCB) Granted Protection until 2027 on Broad Transgenic Protein Production Patent, and is Also Granted New Patent on Recombinant Anti-Thrombin Produced Transgenically
5/20/2011 8:36:02 AM
GTC Biotherapeutics, Inc. (GTC) (a wholly-owned subsidiary of LFB Biotechnologies S.A.S., Les Ulis, France), announced today that the United States Patent and Trademark Office (USPTO) granted (to GTC) a patent covering DNA constructs for the production of any therapeutic protein in the milk of any transgenic animal. This “Broad DNA” patent extends to 2027. GTC’s intellectual property position also includes a United States Patent extending to 2021 covering methods for the production of any therapeutic protein in the milk of non-human transgenic mammals. With this event, GTC’s intellectual property (estate) includes patents in the United States expiring as late as 2027 covering DNA constructs and methods for the production of any therapeutic protein in the milk of transgenic mammals.
comments powered by